SHANGHAI, China, June 1, 2026 — ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (ImmuneOnco; HKEX Stock Code: 01541.HK) announced today that the latest Phase I clinical data for its proprietary VEGF×PD-L1 bispecific antibody, palverafusp α (IMM2510), were officially presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract No. 8580). The data demonstrated that IMM2510 not only achieved significant efficacy but also exhibited an excellent safety profile distinct from other agents in patients with advanced squamous non-small cell lung cancer (Sq-NSCLC) who had progressed on prior immunotherapy (IO). This marks the fourth consecutive year that IMM2510 has been featured at ASCO, the premier global oncology conference, further validating the robust global R&D capabilities and sustained potential of this blockbuster bispecific therapy.

The 2026 ASCO Annual Meeting was held in Chicago from May 29 to June 2, 2026 (local time). As the most authoritative academic conference in global oncology, it showcases the most cutting-edge clinical research achievements.

Poster Presentation

Phase I study of IMM2510, a PD-L1/VEGF bispecific antibody, in participants with advanced IO-treated SQ-NSCLC

Abstract No.: 8580

Presentation Type: Poster Presentation

Session Title: Lung Cancer—Non-Small Cell Metastatic

Key Highlights of the Study Abstract:

The selected poster detailed the clinical data of IMM2510 in patients with advanced Sq-NSCLC who had progressed following IO treatment. As of December 31, 2025, a total of 32 patients with IO-pretreated Sq-NSCLC were enrolled and received IMM2510 monotherapy. The vast majority (25 patients) received the recommended Phase 2 dose (RP2D) of 20 mg/kg during the dose-expansion cohort.

● Overcoming the Challenge of Immune Resistance

The study background highlights that despite the widespread use of immune checkpoint inhibitors, patients with advanced NSCLC still face significant unmet medical needs. This study specifically targeted patients who progressed after IO treatment, aiming to validate the potential of IMM2510 as a second-line and later-line therapy.

● Significant Clinical Benefit

Outstanding Disease Control:

As of the December 31, 2025 data cutoff, among 22 efficacy-evaluable subjects, the objective response rate (ORR) was 27.3% (6/22), and the disease control rate (DCR) reached 81.8% (18/22). Notably, further efficacy analysis indicated a stronger signal at the 20 mg/kg RP2D. An independent analysis of 17 evaluable patients in this dose cohort showed a DCR as high as 88.2% (15/17).

Positive Survival Data:

The median progression-free survival (mPFS) was 9.4 months (median follow-up: 8.3 months), the median duration of response (DoR) was 11.1 months, and the median overall survival (mOS) had not been reached.

Controllable Safety Profile:

Addressing the clinical pain points of IO-resistant Sq-NSCLC patients—who are often elderly, have poor performance status (PS), and are intolerant to chemotherapy—IMM2510 demonstrated significant safety advantages. The data showed an exceptionally low rate of permanent discontinuation due to adverse events (AEs) of only 3.1%, which is significantly superior to historical data for some comparable products (discontinuation rate of ~22.2%). No Grade ≥3 immune-related adverse events (irAEs) were observed in the study. This characteristic provides a unique advantage for long-term chronic disease management, alleviating concerns among clinicians and patients regarding "treatment interruption."

● Addressing Refractory Baselines in the Face of Immune Resistance

This study enrolled a highly challenging, heavily pretreated patient population. All subjects had received a median of 2 lines (range: 1–5) of prior systemic anti-tumor therapy, and 31.3% of the patients had low PD-L1 expression (TPS <1%). This high proportion of refractory baseline characteristics precisely addresses the core clinical pain point of IO failure due to low PD-L1 expression, strongly validating the exceptional clinical potential of IMM2510 in breaking through the bottleneck of immune resistance and providing new treatment options for refractory patients.

● Future Development Plans

Based on the positive data from the Phase I study and exposure-response analysis, 20 mg/kg Q2W has been established as the RP2D, and subsequent Phase III clinical studies are currently being planned.

Dr. Wenzhi Tian, Chairman, CEO, and CSO of ImmuneOnco, stated:

"The data presented for IMM2510 at ASCO not only affirms our previous research but also serves as strong evidence of the potential of bispecific antibodies in solid tumor treatment. The mPFS of 9.4 months and the extremely low discontinuation rate demonstrate the outstanding potential to replace existing standard-of-care therapies. We will take this opportunity to accelerate the global clinical development of this drug, committed to bringing superior treatment options to cancer patients worldwide through differentiated innovative therapies."

Dr. Zhuli Wu, Chief Medical Officer of ImmuneOnco, stated:

"For patients with advanced Sq-NSCLC who have progressed on immunotherapy, clinical treatment options remain extremely limited, representing a massive unmet need. The excellent safety profile and positive survival benefits demonstrated by IMM2510 highlight the tremendous value of this drug in overcoming immune resistance and benefiting more frail patients. We will continue to advance subsequent Phase III clinical studies with rigorous scientific standards, striving to bring this innovative therapy to more patients with refractory lung cancer as soon as possible."